Segment Information

12 Months Ended

Dec. 31, 2011

Segment Information [Abstract]

Segment Information

25.    Segment Information

We operate as one business segment, which is the business of discovering, developing, manufacturing and marketing therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders and therefore, our chief operating decision-maker manages the operations of our Company as a single operating segment. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.

Revenue by product is summarized as follows:

	For the Years Ended December 31,
	2011						2010						2009
(In millions)	United States		Rest of World		Total		United States		Rest of World		Total		United States		Rest of World		Total
AVONEX	$	1,628.3	$	1,058.3	$	2,686.6	$	1,491.6	$	1,026.8	$	2,518.4	$	1,406.2	$	916.7	$	2,322.9
TYSABRI		326.5		753.0		1,079.5		252.8		647.4		900.2		231.8		544.2		776.0
Other		—		70.0		70.0		—		51.5		51.5		—		54.0		54.0
Total product revenues	$	1,954.8	$	1,881.3	$	3,836.1	$	1,744.4	$	1,725.7	$	3,470.1	$	1,638.0	$	1,514.9	$	3,152.9

Geographic Information

The following tables contain certain financial information by geographic area:

December 31, 2011 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	1,954.8	$	1,163.3	$	377.5	$	88.7	$	251.8	$	3,836.1
Revenues from unconsolidated joint business	$	878.8	$	29.9	$	—	$	30.7	$	57.2	$	996.6
Other revenues from external customers	$	187.0	$	28.3	$	0.6	$	—	$	—	$	215.9
Long-lived assets	$	1,012.5	$	816.6	$	1.6	$	5.3	$	2.4	$	1,838.4
December 31, 2010 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	1,744.4	$	1,090.7	$	362.4	$	69.0	$	203.6	$	3,470.1
Revenues from unconsolidated joint business	$	906.3	$	95.3	$	—	$	26.0	$	49.6	$	1,077.2
Other revenues from external customers	$	136.0	$	32.6	$	0.5	$	—	$	—	$	169.1
Long-lived assets	$	1,100.3	$	717.4	$	1.5	$	5.4	$	1.6	$	1,826.2
December 31, 2009 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	1,638.0	$	913.7	$	374.8	$	47.9	$	178.5	$	3,152.9
Revenues from unconsolidated joint business	$	839.2	$	190.2	$	—	$	24.1	$	41.4	$	1,094.9
Other revenues from external customers	$	102.8	$	26.2	$	0.5	$	—	$	—	$	129.5
Long-lived assets	$	1,092.7	$	705.6	$	1.4	$	3.6	$	2.1	$	1,805.4

(1) Represents amounts related to Europe less those attributable to Germany.

Revenues from Unconsolidated Joint Business

Approximately 20%, 23% and 25% of our total revenues in 2011, 2010 and 2009, respectively, are derived from our joint business arrangement with Genentech. For additional information related to our collaboration with Genentech, please read Note 20, Collaborations to these consolidated financial statements.

Significant Customers

We recorded revenue from two wholesale distributors accounting for 18% and 10% of gross product revenues in 2011, 18% and 11% of gross product revenue in 2010, and 18% and 12% of gross product revenues in 2009.

Other

As of December 31, 2011, 2010 and 2009, approximately $668.5 million, $644.7 million and $665.8 million, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.